These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 5972404)

  • 21. Possible functional differentiation between the stores from which adrenergic nerve stimulation, tyramine and amphetamine release noradrenaline.
    Obianwu HO
    Acta Physiol Scand; 1969; 75(1):92-101. PubMed ID: 5785154
    [No Abstract]   [Full Text] [Related]  

  • 22. Tyramine and monoamine oxidase inhibitors as modulators of the mitochondrial membrane permeability transition.
    Marcocci L; De Marchi U; Salvi M; Milella ZG; Nocera S; Agostinelli E; Mondovi B; Toninello A
    J Membr Biol; 2002 Jul; 188(1):23-31. PubMed ID: 12172644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Selective inhibition of type A monoamine oxidase by pyrazidol].
    Mashkovskiĭ MD; Gorkin VZ; Verevkina IV; Asnina VV; Tupikina SM
    Biull Eksp Biol Med; 1981 Feb; 91(2):169-71. PubMed ID: 7225552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Displacement of in vivo binding of [3H]brofaromine to rat intestinal monoamine oxidase A by orally administered tyramine.
    Waldmeier PC; Stöcklin K
    Eur J Pharmacol; 1992 Jun; 216(2):243-7. PubMed ID: 1397011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of vesicular storage and monoamine oxidase activity on [11C]phenylephrine kinetics: studies in isolated rat heart.
    Raffel DM; Wieland DM
    J Nucl Med; 1999 Feb; 40(2):323-30. PubMed ID: 10025842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Experimental findings on tyramine-dependent release of noradrenaline in various parts of the heart under the influence of practolol].
    Brisse B; Bender F
    Z Kardiol; 1975 Oct; 64(10):941-4. PubMed ID: 56095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monoamine oxidase inhibitors and pressor response to dietary amines].
    Tipton KF
    Vopr Med Khim; 1997; 43(6):494-503. PubMed ID: 9503566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacology of reversible monoamine oxidase-A inhibitors.
    Bieck PR; Antonin KH; Schmidt E
    Clin Neuropharmacol; 1993; 16 Suppl 2():S34-41. PubMed ID: 8313395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of methyldopa and related agents on pressor responses to tyramine in reserpine-pretreated rats and dogs.
    Torchiana ML; Wenger HC; Stavorski J; Ludden CT; Stone CA
    J Pharmacol Exp Ther; 1966 Feb; 151(2):242-52. PubMed ID: 5932601
    [No Abstract]   [Full Text] [Related]  

  • 30. [Action of some derivatives of pyrazolinone on the pressor activity of tyramine].
    Patané S; Arrigo Reina R
    Boll Soc Ital Biol Sper; 1969 Aug; 45(16):1081-3. PubMed ID: 5374943
    [No Abstract]   [Full Text] [Related]  

  • 31. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
    Yáñez M; Fraiz N; Cano E; Orallo F
    Eur J Pharmacol; 2006 Aug; 542(1-3):54-60. PubMed ID: 16828740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
    Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
    Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Some puzzling pharmacological effects of monoamine oxidase inhibitors.
    Knoll J; Magyar K
    Adv Biochem Psychopharmacol; 1972; 5():393-408. PubMed ID: 5066229
    [No Abstract]   [Full Text] [Related]  

  • 35. Potentiation of the noradrenaline-releasing action of tyramine by monoamine oxidase inhibitors.
    Spano PF
    J Pharm Pharmacol; 1966 Aug; 18(8):548. PubMed ID: 4381864
    [No Abstract]   [Full Text] [Related]  

  • 36. Tyramine and vanadate synergistically stimulate glucose transport in rat adipocytes by amine oxidase-dependent generation of hydrogen peroxide.
    Marti L; Morin N; Enrique-Tarancon G; Prevot D; Lafontan M; Testar X; Zorzano A; Carpéné C
    J Pharmacol Exp Ther; 1998 Apr; 285(1):342-9. PubMed ID: 9536030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [On the role of noradrenaline of the adipose tissue. II. Subcellular localization of the noradrenaline].
    Congiu S; Musinu C; Spano PF; Gessa GL
    Boll Soc Ital Biol Sper; 1967 Jul; 43(14):852-4. PubMed ID: 6056689
    [No Abstract]   [Full Text] [Related]  

  • 38. Iron (III) attenuates hydroxyl radical generation accompanying non-enzymatic oxidation of noradrenaline in the rat heart.
    Obata T; Yamanaka Y
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):158-63. PubMed ID: 11819034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retention of exogenous norepinephrine and recovery of the responses to tyramine and 1,1-dimethyl-4-phenylpiperazinium iodide after reserpine.
    Bhagat B; Bhattacharya IC; Dhalla NS
    J Pharmacol Exp Ther; 1966 Sep; 153(3):434-9. PubMed ID: 5922321
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action.
    Lenke D; Gries J; Kretzschmar R
    Arzneimittelforschung; 1981; 31(9a):1558-65. PubMed ID: 7197970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.